Anna Gielicz

Anna Gielicz

Auto-generated profile, based on publicly available information

Anna Gielicz

2nd Department of Internal Medicine Jagiellonian University Medical College Krakow Poland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2024 in Allergy
Verified
Journal Article
Open access
LMLucyna Mastalerz
Lucyna Mastalerz
GTGabriela Trąd
Gabriela Trąd
PSPiotr Szatkowski
Piotr Szatkowski
AĆAdam Ćmiel
Adam Ćmiel
AGAnna Gielicz
Anna Gielicz
MSMarek Sanak
Marek Sanak
Background: 15‐oxo‐eicosatetraenoic acid (15‐oxo‐ETE), is a product of arachidonic acid (AA) metabolism in the 15‐lipoxygenase‐1 (15‐LOX‐1) pathway. 15‐oxo‐ETE was overproduced in the nasal polyps of patients with nonsteroidal anti‐inflammatory drug–exacerbated respiratory disease (N‐ERD). In this study we investigated the systemic biosynthesis of 15‐oxo‐ETE and leukotriene E4 (LTE4) and assessed their diagnostic value to identify patients with N‐ERD.Methods: The study included 64 patients with N‐ERD, 59 asthmatics who tolerated aspirin well (ATA), and 51 healthy controls. A thorough clinical characteristics of asthmatics included computed tomography of paranasal sinuses. Plasma and urinary 15‐oxo‐ETE levels, and urinary LTE4 excretion were measured using high‐performance liquid chromatography and tandem mass spectrometry. Repeatability and precision of the measurements were tested.Results: Plasma 15‐oxo‐ETE levels were the highest in N‐ERD (p < .001). A receiver operator characteristic (ROC) revealed that 15‐oxo‐ETE had certain sensitivity (64.06% in plasma, or 88.24% in urine) for N‐ERD discrimination, while the specificity was rather limited. Modeling of variables allowed to construct the Aspirin Hypersensitivity Diagnostic Index (AHDI) based on urinary LTE4‐to‐15‐oxo‐ETE excretion corrected for sex and the Lund‐Mackay score of chronic rhinosinusitis. AHDI outperformed single measurements in discrimination of N‐ERD among asthmatics with an area under ROC curve of 0.889, sensitivity of 81.97%, specificity of 87.23%, and accuracy of 86.87%.Conclusions: We confirmed 15‐oxo‐ETE as a second to cysteinyl leukotrienes biomarker of N‐ERD. An index based on these eicosanoids corrected for sex and Lund‐Mackay score has a similar diagnostic value as gold standard oral aspirin challenge in the studied group of patients with asthma.

1 January 2020 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
MSMarcin Surmiak
Marcin Surmiak
AGAnna Gielicz
Anna Gielicz
DSDarko Stojkov
Darko Stojkov
RSRafał Szatanek
Rafał Szatanek
KWKatarzyna Wawrzycka-Adamczyk
Katarzyna Wawrzycka-Adamczyk
MSMarek Sanak
Marek Sanak
Marcin Surmiak, Anna Gielicz, Darko Stojkov, Rafał Szatanek, Katarzyna Wawrzycka-Adamczyk, Shida Yousefi, Hans-Uwe Simon, Marek Sanak

19 July 2026 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
RKRadosław Kacorzyk
Radosław Kacorzyk
PSPiotr Szatkowski
Piotr Szatkowski
AGAgnieszka Gawlewicz‐Mroczka
Agnieszka Gawlewicz‐Mroczka
AĆAdam Ćmiel
Adam Ćmiel
AGAnna Gielicz
Anna Gielicz
LMLucyna Mastalerz
Lucyna Mastalerz
Background: Up to 50% of patients with nonsteroidal anti‐inflammatory drug‐exacerbated respiratory disease (N‐ERD) exhibit a noneosinophilic airway inflammatory phenotype, with paucigranulocytic asthma being the most prevalent. The aim was to identify clusters within N‐ERD and aspirin‐tolerant asthma (ATA) controls with a paucigranulocytic asthma phenotype. Methods: Two separate hierarchical cluster analyses were performed using 23 variables in 36 N‐ERD patients and 19 ATA controls. Variables included demographic, clinical, treatment‐related, and hematologic parameters; sputum cytology; sinus computed tomography findings; and eicosanoid levels in induced sputum supernatant (ISS) and urine. Results: Two clusters were identified in each group: 1 N‐ERD , 2 N‐ERD , 1 ATA , and 2 ATA . Cluster 1 N‐ERD patients had less severe asthma and required lower doses of inhaled corticosteroids (ICS) but showed higher blood eosinophil counts, Lund‐Mackay (LM) scores, and ISS leukotriene E 4 (LTE 4 ) levels than those in cluster 2 N‐ERD . Cut‐off values defining a T2‐high paucigranulocytic asthma profile in N‐ERD included LM score ≥ 18, blood eosinophils ≥ 300 cells/mm 3 , and ISS LTE 4 ≥ 30 pg/mL, with the LM score demonstrating the highest AUC at 0.8. Among ATA controls, cluster 1 ATA had more severe asthma, higher ICS doses, more severe sinonasal disease, and increased ISS leukotriene D 4 and LTE 4 levels compared with cluster 2 ATA . Conclusion: Two clusters were identified among N‐ERD patients with a paucigranulocytic asthma phenotype. Cluster 1 N‐ERD was characterized by milder asthma, more severe sinonasal disease, elevated blood eosinophil counts, and elevated ISS LTE 4 . This T2‐high‐like cluster may represent a subgroup requiring further evaluation for anti‐T2 biologic therapy targeting chronic rhinosinusitis with nasal polyps, although further validation is required.